Kass M, Cheetham J, Duzman E, Burke P J
Am J Ophthalmol. 1986 Aug 15;102(2):159-63. doi: 10.1016/0002-9394(86)90137-6.
Fourteen subjects known to be corticosteroid responders participated in a double-masked, randomized study comparing the ocular hypertensive effect of 0.25% fluorometholone suspension with that of 0.1% dexamethasone sodium phosphate. Subjects instilled one drop of fluorometholone in one eye and one drop of dexamethasone in the fellow eye four times daily for up to six weeks. Although both medications increased intraocular pressure, endpoint substitution analysis demonstrated that mean intraocular pressure increases from baseline in the eyes treated with fluorometholone were significantly lower than those in the eyes treated with dexamethasone at weeks 2, 4, and 6 (P less than or equal to .05). Also, mean maximum intraocular pressure was significantly lower in the eyes treated with fluorometholone than in the eyes treated with dexamethasone (P = .001). These results indicated that 0.25% fluorometholone is less likely to increase intraocular pressure in corticosteroid responders than 0.1% dexamethasone.
14名已知对皮质类固醇有反应的受试者参与了一项双盲随机研究,比较0.25%氟米龙混悬液与0.1%地塞米松磷酸钠的眼压升高作用。受试者每天4次在一只眼中滴入一滴氟米龙,在另一只眼中滴入一滴地塞米松,持续6周。尽管两种药物均使眼压升高,但终点替代分析表明,在第2、4和6周时,用氟米龙治疗的眼睛眼压较基线的平均升高幅度显著低于用地塞米松治疗的眼睛(P≤0.05)。此外,用氟米龙治疗的眼睛的平均最高眼压显著低于用地塞米松治疗的眼睛(P = 0.001)。这些结果表明,在对皮质类固醇有反应的人群中,0.25%氟米龙比0.1%地塞米松更不易升高眼压。